Fig. 2From: Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinomaRadiosensitivity of IGROV1 cells. The radiosensitivity was determined by colony-forming assays after combined treatments with 177Lu-DOTA-chCE7 (range: from 0.01–5.0 MBq/ml, for 8 h) and MK1775 (applied simultaneously, 48 h post, or 48 h pre RIC with a concentration of half IC50)Back to article page